JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2003; 41:1561-1567, doi:10.1016/S0735-1097(03)00189-X
© 2003 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moon, J. C. C.
Right arrow Articles by Pennell, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moon, J. C. C.
Right arrow Articles by Pennell, D. J.

CLINICAL RESEARCH

Toward clinical risk assessment inhypertrophic cardiomyopathy withgadolinium cardiovascular magnetic resonance

James C. C. Moon, MB, BCh*, William J. McKenna, FACC, FESC{dagger}, Jane A. McCrohon, FRACP, PhD*, Perry M. Elliott, MD, MRCP, FACC{dagger}, Gillian C. Smith, BSc*{dagger} and Dudley J. Pennell, MD, FRCP, FESC, FACC*,*

* Centre for Advanced Magnetic Resonance in Cardiology (CAMRIC), Royal Brompton Hospital, London, United Kingdom
{dagger} Department of Cardiological Sciences, St. George’s Hospital Medical School, London, United Kingdom

Manuscript received May 20, 2002; revised manuscript received September 25, 2002, accepted October 4, 2002.

* Reprint requests and correspondence: Dr. Dudley J. Pennell, Professor of Cardiology, CMR Unit, Royal Brompton Hospital, Sydney Street, London SW3 6NP, United Kingdom.
d.pennell{at}ic.ac.uk


   Abstract
Top
 Abstract
Methods
 Results
 Discussion
 References
 
OBJECTIVES: We sought to assess whether hyperenhancement by gadolinium cardiovascular magnetic resonance (CMR) occurs in hypertrophic cardiomyopathy (HCM) and correlates with the risk of heart failure and sudden death.

BACKGROUND: The myocardial interstitium is abnormal in HCM at post-mortem. Focally increased interstitial myocardial space appears as hyperenhancement with gadolinium CMR.

METHODS: In a blinded, prospective study, HCM patients were selected for the presence (n = 23) or absence (n = 30) of an increased clinical risk of sudden death and/or progressive adverse left ventricular (LV) remodeling. Gadolinium-enhanced CMR was performed.

RESULTS: Myocardial hyperenhancement was found in 42 patients (79%), affecting 10.9% (range 0% to 48%) of the LV mass. There was a greater extent of hyperenhancement in patients with progressive disease (28.5% vs. 8.7%, p < 0.001) and in patients with two or more risk factors for sudden death (15.7% vs. 8.6%, p = 0.02). Improved discrimination was seen in patients >40 years old (29.6% vs. 6.7%, p < 0.001) for progressive disease and for patients <40 years old for risk factors for sudden death (15.7% vs. 2.1%, p = 0.002). Patients with diffuse rather than confluent enhancement had two or more risk factors for sudden death (87% vs. 33%, p = 0.01).

CONCLUSIONS: Gadolinium CMR reveals myocardial hyperenhancement in HCM. The extent of hyperenhancement is associated with progressive ventricular dilation and markers of sudden death.

Abbreviations and Acronyms
  CMR = cardiovascular magnetic resonance
  DTPA = diethylenetriaminepentaacetic acid
  FISP = fast imaging with steady-state precession
  HCM = hypertrophic cardiomyopathy
  LV = left ventricle/ventricular
  LVH = left ventricular hypertrophy

An important minority of patients with hypertrophic cardiomyopathy (HCM) are at high risk of sudden death and/or progressive left ventricular (LV) impairment (1,2). Predicting these outcomes is a major management challenge, and new methods are needed. The abnormal myocardial substrate is probably the key determinant of clinical events (3–6), consisting of interstitial fibrosis, myocardial disarray, small-vessel disease, and macroscopic scarring. Fibrosis caused by myocardial infarction can be detected by cardiovascular magnetic resonance (CMR) using the extra-cellular fluid tracer gadolinium-diethylenetriaminepentaacetic acid (DTPA), or gadolinium CMR (7–9). We hypothesized that abnormal myocardium would be demonstrated in vivo by hyperenhancement on gadolinium CMR in HCM and that hyperenhancement would be associated with markers of risk of sudden death and the presence of progressive disease.


   Methods
Top
 Abstract
 Methods
Results
 Discussion
 References
 
Patients.   This was a blinded, prospective study of 53 patients selected from a dedicated HCM clinic at St. George’s Hospital, London, which consists of 1,074 patients. The selected patients fulfilled conventional criteria for HCM with left ventricular hypertrophy (LVH) ≥15 mm at some time point in their disease (10). The only exclusion criterion was the presence of an implantable device. We aimed to recruit approximately equal numbers of patients with two or more risk factors or progressive disease, as those without these factors. Four patients had undergone gradient reduction therapy (two surgical myectomies and two transcatheter alcohol ablations). All patients gave written, informed consent, and the institutional Ethical Review Committee approved the study.

Sudden death risk stratification.   Five clinical risk factors for sudden death were used to stratify patients: a family history of HCM and sudden premature cardiac death; unexplained syncope at any time during follow-up; non-sustained ventricular tachycardia; an abnormal blood pressure response during upright exercise testing in subjects ≤40 years old; and echocardiographic presence of severe LVH ≥30 mm.

Diagnosis of progressive disease.   Progressive disease was defined as a decrease in maximal LV wall thickness ≥5mm and an increase in LV end-systolic dimension ≥5mm during five or more years of follow-up on a serial in-house echocardiogram. This definition selects a poor prognostic group, including patients with "pseudonormalization" of initial supra-systolic function and LVH on the way to a dilated phase.

The CMR technique.   CMR was performed on a 1.5-T Sonata scanner (Siemens, Erlangen, Germany). Fast imaging with steady-state precession (FISP) sequential short-axis cine loops (7-mm slice thickness, 3-mm gap) were acquired. A peripheral bolus injection of gadolinium-DTPA (0.1 mmol/kg) was then given, and contrast-enhanced images were acquired using a segmented inversion-recovery sequence (11), with the following modifications: imaging was started at 5 min; segmentation was from 17 to 23 lines; inversion pulse every 2 to 3 heart beats depending on the RR interval and heart rate variability; a 90° presaturation pulse was placed over the cerebrospinal fluid to eliminate ghosting; and two-chamber, four-chamber, and all short-axis views were acquired twice with different phase-encoding direction and meticulous attention to the inversion time. The typical voxel size was 1.7 x 1.4 x 8 mm.

Image analysis.   Ventricular function was analyzed from the serial short-axis true FISP cine loops using manual segmentation (CMRtools Imperial College, London). End-diastolic volume, end-systolic volume, ejection fraction, and myocardial volume of the LV were calculated. For the gadolinium-enhanced images, hyperenhancement was only considered to be present if it was also present in the same slice after swapping phase encoding, thus excluding artifact. Analysis was performed by manually defining the areas of hyperenhancement on all short-axis slices from the base to apex. Summing the areas yielded the total volume of hyperenhancement, which was expressed as a percentage of total myocardium.

Statistical analysis.   Non-parametric Wilcoxon rank comparisons were made to compare the extent of hyperenhancement between patients with ≤1 and ≥2 risk factors for sudden death, and between patients with and without the presence of progressive disease. Linear regression analysis was performed to compare the extent of hyperenhancement with patient age, LV function, and mass.


   Results
Top
 Abstract
 Methods
 Results
Discussion
 References
 
Patient baseline characteristics.   The baseline characteristics of the patients are given in Table 1. There were 0, 1, 2, 3, 4, and 5 risk factors in 19, 16, 13, 3, 2, and 0 patients, respectively. Of 34 patients with >5 years of follow-up, nine had progressive disease (of these, four patients also had ≥2 risk factor for sudden death). There was no age difference between patients with and without progressive disease (49 vs. 51 years, p = 0.8), but patients with ≥2 risk factors for sudden death were younger than patients with ≤1 risk factors for sudden death (35 vs. 53 years, p < 0.001).


View this table:
[in this window]
[in a new window]
  		Table 1 Demographics and Baseline Characteristics

 
Extent of hyperenhancement.   Myocardial hyperenhancement was present in 42 patients (79%). The mean percentage of myocardium involved was 10.9 ± 11% (range 0% to 48%). Abnormal myocardium was not visible without contrast (Fig. 1). Regions of hyperenhancement had a mean image intensity of 27; remote myocardium, 5.7; and background noise, 4.24. The percentage elevation in signal from hyperenhanced regions was 430% (range 120% to 1,000%); the mean difference in image intensity between hyperenhanced and remote regions was 16 standard deviations of remote region intensity. There was no relationship between percentage hyperenhancement and patient age (r = 0.1, p = 0.47). The percentage hyperenhancement correlated weakly with LV mass index (r = 0.24, p = 0.04), end-diastolic volume (r = 0.42, p = 0.002), and end-systolic volume (r = 0.64, p < 0.001) and inversely with ejection fraction (r = 0.64, p < 0.001).



View larger version (157K):
[in this window]
[in a new window]
  		Figure 1 Pre- and post-contrast images demonstrating hyperenhancement. The pre-contrast images are the diastolic frames of fast imaging with steady-state precession cine loops. In the post-contrast images, normal myocardium appears dark. There is a large area of septal hyperenhancement, with additional papillary muscle hyperenhancement and subendocardial hyperenhancement of the lateral wall. The patient is a 33-year-old female with two risk factors for sudden death. Eight years previously, echocardiography demonstrated marked asymmetric septal hypertrophy, but the ventricle is now thinning and dilating and left bundle branch block has developed. The total extent of hyperenhancement was 25% of the left ventricular (LV) mass. LA = left atrium; RA = right atrial; RV = right ventricle.

 
There was more hyperenhancement in patients with progressive disease than in those without (28.5% vs. 8.7%, p < 0.001) (Fig. 2A). This remained significant when patients with ≥2 risk factors for sudden death were excluded (28.4% vs. 6.9%, p = 0.04) (Fig. 2B). This finding appeared more marked in patients >40 years old (29.6% vs. 6.7%, p < 0.001) (Fig. 2C), and remained significant when patients with ≥2 risk factors for sudden death were excluded (28.4% vs. 6.9%, p = 0.04) (Fig. 2D). There was greater hyperenhancement in patients with ≥2 risk factors for sudden death (15.7% vs. 8.6%, p = 0.02) (Fig. 3A). This remained significant when patients with progressive disease were excluded (12.0% vs. 5.3%, p = 0.02) (Fig. 3B). This finding appeared more marked in patients <40 years old (15.7% vs. 2.1%, p = 0.002) (Fig. 3C), which remained significant when patients with progressive disease were excluded (14.1% vs. 2.1%, p = 0.003) (Fig. 3D).



View larger version (22K):
[in this window]
[in a new window]
  		Figure 2 Extent of hyperenhancement and presence of progressive disease. Hyperenhancement was associated with the presence of progressive disease (A), even when patients at high risk of sudden death were excluded (B), and appeared more marked in patients >40 years old, regardless of the risk of sudden death (C, D). rfsd = risk factors for sudden death.

 


View larger version (23K):
[in this window]
[in a new window]
  		Figure 3 Extent of hyperenhancement and clinical risk factors for sudden death. Hyperenhancement was associated with an increased clinical risk of sudden death (A), even when patients with progressive disease were excluded (B), and appeared more marked in patients <40 years old, regardless of the presence of progressive disease (C, D).

 
Patterns of hyperenhancement.   Specific patterns of hyperenhancement were evident. There were two broad patterns: diffuse hyperenhancement and confluent hyperenhancement. Patients with diffuse (n = 8) rather than confluent (n = 21) enhancement had ≥2 risk factors for sudden death (87% vs. 33%, p = 0.01). Further classification could be made, but the number of patients is too small to draw strong conclusions. The distributions are shown in Figure 4 and Table 2.



View larger version (79K):
[in this window]
[in a new window]
  		Figure 4 (A and B) Patterns of hyperenhancement in hypertrophic cardiomyopathy by cardiovascular magnetic resonance. The patterns of hyperenhancement are grouped into diffuse or confluent types (upper rows: long-axis, vertical, or horizontal; lower rows: short-axis views). These were further subclassified as shown. The different patterns may have clinical or prognostic significance, and this qualitative classification may complement the overall quantification of hyperenhancement. RV = right ventricular.

 

View this table:
[in this window]
[in a new window]
  		Table 2 Associations Between Pattern of Hyperenhancement and Clinical Phenotype

 

   Discussion
Top
 Abstract
 Methods
 Results
 Discussion
References
 
Identifying patients at high and low risk is an important but problematic aspect of the clinical management of HCM, particularly with the availability of an effective but not hazard-free treatment option—the implantable cardioverter-defibrillator (12). Likewise, there are few markers for the risk of heart failure before LV dysfunction is evident (13,14). Neither the genotype nor the extent of hypertrophy fully predicts the clinical risk (15–17). Ideally, assessment would involve a global assessment of the underlying histology, the substrate for myocardial pump failure, and arrhythmia. The histology consists of myocardial disarray (18) and small-vessel disease or replacement fibrosis (19–21).

Gadolinium-enhanced CMR has been validated for the detection of irreversible injury in myocardial infarction (22). Hyperenhancement is considered to occur in areas of expanded extracellular space. Gadolinium bound to DTPA diffuses into the interstitial space between cells but not across cell membranes. In fibrosis and extracellular expansion, there is a greater extracellular space for gadolinium-DTPA accumulation, and the distribution kinetics are slower than normal myocardium (8,9). These two effects result in a delayed and persistently higher relative concentration of gadolinium in areas in the heart where extracellular tissue is abnormal. We therefore hypothesized that this technique might prove useful in the clinical assessment of the myocardial substrate in HCM. In myocardial infarction, fibrosis always includes the subendocardium because of the nature of the ischemic wave front that starts there. In HCM, gadolinium enhancement could occur in myocardial replacement fibrosis, but this may well show different characteristics. First, fibrosis in HCM can occur throughout the myocardial wall, even with subendocardial sparing. In addition, areas of focal myocardial disarray and fine interstitial fibrosis may be seen. Therefore, the distribution and pattern of gadolinium uptake will be different between these two conditions, as we have confirmed in this study.

Histologic correlations between hyperenhancement and pathology are not yet available. We believe that hyperenhancement is the result of a number of pathologic processes that result in different forms of fibrosis (replacement scar or myocyte dropout) or in relation to myocardial disarray and consequent local interstitial expansion. The different patterns of hyperenhancement seen are likely to be linked to the different pathologic processes occurring in different patients, and the different stages that such processes had reached at the time of scanning.

Study limitations.   In this preliminary study, the HCM patients were highly selected, which could introduce a referral bias. Some patients had both progressive disease and two or more risk factors for sudden death, but this reflects the HCM population. Although this complicated the interpretation of the findings, exclusion of these patients did not alter the results. Future work is required to identify histologic correlations and prospective prediction of events based on hyperenhancement findings.

Conclusions.   Areas of hyperenhancement are seen in HCM by CMR. The extent of hyperenhancement is linked with progressive disease and markers of clinical risk for sudden death.


   Acknowledgments
 
The authors thank Professor Philip Poole-Wilson for advice on trial design and reading of the manuscript.


   Footnotes
 
Prof. McKenna and Dr. Moon were supported by the British Heart Foundation. Dr. McCrohon was supported by CORDA, The Heart Charity. CAMRIC was supported by a grant from the British Heart Foundation and receives research support from Siemens AG, Erlangen, Germany.


   References
Top
 Abstract
 Methods
 Results
 Discussion
 References
 

  1. Cannan CR, Reeder GS, Bailey KR, et al. Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990. Circulation. 1995;92:2488–2495[Abstract/Free Full Text]
  2. Frank S, Braunwald E. Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history. Circulation. 1968;37:759–788[Abstract/Free Full Text]
  3. Varnava AM, Elliott PM, Mahon N, et al. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol. 2001;88:275–279[CrossRef][Medline]
  4. Varnava AM, Elliott PM, Sharma S, et al. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000;84:476–482[Abstract/Free Full Text]
  5. Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol. 1979;43:1086–1102[CrossRef][Medline]
  6. Spirito P, Seidman CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775–785[Free Full Text]
  7. Wu E, Judd RM, Vargas JD, et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non–Q-wave myocardial infarction. Lancet. 2001;357:21–28[CrossRef][Medline]
  8. Kim RJ, Chen EL, Lima JAC, et al. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318–3326[Abstract/Free Full Text]
  9. Flacke SJ, Fischer SE, Lorenz CH. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology. 2001;218:703–710[Abstract/Free Full Text]
  10. Report of the 1995 World Health Organisation. International Society and Federation of Cardiomyopathy Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996;93:841–842[Free Full Text]
  11. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218:215–223[Abstract/Free Full Text]
  12. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212–2218[Abstract/Free Full Text]
  13. Ikeda H, Maki S, Yoshida N, et al. Predictors of death from congestive heart failure in hypertrophic cardiomyopathy. Am J Cardiol. 1999;83:1280–1283[CrossRef][Medline]
  14. Spirito P, Maron BJ, Bonow RO, et al. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol. 1987;59:123–129[CrossRef]
  15. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001;33:655–670[CrossRef][Medline]
  16. Elliott PM, Gimeno Blanes JR, Mahon NG, et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357:420–424[CrossRef][Medline]
  17. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778–1785[Abstract/Free Full Text]
  18. Davies MJ. The current status of myocardial disarray in hypertrophic cardiomyopathy. Br Heart J. 1984;51:361–363[Free Full Text]
  19. St. John Sutton MG, Lie JT, Anderson KR, et al. Histopathological specificity of hypertrophic obstructive cardiomyopathy: myocardial fibre disarray and myocardial fibrosis. Br Heart J. 1984;44:433–443
  20. Maron BJ, Wolfson JK, Epstein SE, et al. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8:545–557[Abstract]
  21. Varnava AM, Elliott PM, Baboonian C, et al. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation. 2001;104:1380–1384[Abstract/Free Full Text]
  22. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;16:1445–1453



This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
N. Reichek and D. Gupta
Hypertrophic Cardiomyopathy: Cardiac Magnetic Resonance Imaging Changes the Paradigm
J. Am. Coll. Cardiol., August 12, 2008; 52(7): 567 - 568.
[Full Text] [PDF]

Home page
 CirculationHome page
T. D. Henry, J. R. Lesser, and D. Satran
Myocardial Fibrosis From Severe Carbon Monoxide Poisoning Detected by Cardiac Magnetic Resonance Imaging
Circulation, August 12, 2008; 118(7): 792 - 792.
[Full Text] [PDF]

Home page
 J Am Coll Cardiol ImgHome page
B. J. Schietinger, G. M. Brammer, H. Wang, J. M. Christopher, K. W. Kwon, A. J. Mangrum, J. M. Mangrum, and C. M. Kramer
Patterns of Late Gadolinium Enhancement in Chronic Hemodialysis Patients
J. Am. Coll. Cardiol. Img., July 1, 2008; 1(4): 450 - 456.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. Sen-Chowdhry and W. J. McKenna
Non-invasive risk stratification in hypertrophic cardiomyopathy: don't throw out the baby with the bathwater
Eur. Heart J., July 1, 2008; 29(13): 1600 - 1602.
[Full Text] [PDF]

Home page
 JNMHome page
B. Sotgia, R. Sciagra, I. Olivotto, G. Casolo, L. Rega, I. Betti, A. Pupi, P. G. Camici, and F. Cecchi
Spatial Relationship Between Coronary Microvascular Dysfunction and Delayed Contrast Enhancement in Patients with Hypertrophic Cardiomyopathy
J. Nucl. Med., July 1, 2008; 49(7): 1090 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll Cardiol ImgHome page
I. S. Syed, S. R. Ommen, J. F. Breen, and A. J. Tajik
Hypertrophic Cardiomyopathy: Identification of Morphological Subtypes by Echocardiography and Cardiac Magnetic Resonance Imaging
J. Am. Coll. Cardiol. Img., May 1, 2008; 1(3): 377 - 379.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. S. Adabag, B. J. Maron, E. Appelbaum, C. J. Harrigan, J. L. Buros, C. M. Gibson, J. R. Lesser, C. A. Hanna, J. E. Udelson, W. J. Manning, et al.
Occurrence and Frequency of Arrhythmias in Hypertrophic Cardiomyopathy in Relation to Delayed Enhancement on Cardiovascular Magnetic Resonance
J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1369 - 1374.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
T. Germans and A. C van Rossum
The use of cardiac magnetic resonance imaging to determine the aetiology of left ventricular disease and cardiomyopathy
Heart, April 1, 2008; 94(4): 510 - 518.
[Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
M. W. Hansen and N. Merchant
MRI of Hypertrophic Cardiomyopathy: Part I, MRI Appearances
Am. J. Roentgenol., December 1, 2007; 189(6): 1335 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
M. W. Hansen and N. Merchant
MRI of Hypertrophic Cardiomyopathy: Part 2, Differential Diagnosis, Risk Stratification, and Posttreatment MRI Appearances
Am. J. Roentgenol., December 1, 2007; 189(6): 1344 - 1352.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
U Sechtem, H Mahrholdt, and H Vogelsberg
Cardiac magnetic resonance in myocardial disease
Heart, December 1, 2007; 93(12): 1520 - 1527.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
R. G Assomull, D. J Pennell, and S. K Prasad
Cardiovascular magnetic resonance in the evaluation of heart failure
Heart, August 1, 2007; 93(8): 985 - 992.
[Full Text] [PDF]

Home page
 CirculationHome page
S. E. Petersen, M. Jerosch-Herold, L. E. Hudsmith, M. D. Robson, J. M. Francis, H. A. Doll, J. B. Selvanayagam, S. Neubauer, and H. Watkins
Evidence for Microvascular Dysfunction in Hypertrophic Cardiomyopathy: New Insights From Multiparametric Magnetic Resonance Imaging
Circulation, May 8, 2007; 115(18): 2418 - 2425.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. A. Shiozaki, T. S. Garcia Santos, E. Artega, and C. E. Rochitte
Myocardial Delayed Enhancement by Computed Tomography in Hypertrophic Cardiomyopathy
Circulation, May 1, 2007; 115(17): e430 - e431.
[Full Text] [PDF]

Home page
 RadiologyHome page
A. S. H. Cheng, M. D. Robson, S. Neubauer, and J. B. Selvanayagam
Irreversible Myocardial Injury: Assessment with Cardiovascular Delayed-Enhancement MR Imaging and Comparison of 1.5 and 3.0 T--Initial Experience
Radiology, March 1, 2007; 242(3): 735 - 742.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
G. P. McCann, C. T. Gan, A. M. Beek, H. W. M. Niessen, A. V. Noordegraaf, and A. C. van Rossum
Extent of MRI Delayed Enhancement of Myocardial Mass Is Related to Right Ventricular Dysfunction in Pulmonary Artery Hypertension
Am. J. Roentgenol., February 1, 2007; 188(2): 349 - 355.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
T. Germans, A. A.M. Wilde, P. A. Dijkmans, W. Chai, O. Kamp, Y. M. Pinto, and A. C. van Rossum
Structural Abnormalities of the Inferoseptal Left Ventricular Wall Detected by Cardiac Magnetic Resonance Imaging in Carriers of Hypertrophic Cardiomyopathy Mutations
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2518 - 2523.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. F. Nagueh and J. J. Mahmarian
Noninvasive Cardiac Imaging in Patients With Hypertrophic Cardiomyopathy
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2410 - 2422.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
P. Sparrow, D. R. Messroghli, S. Reid, J. P. Ridgway, G. Bainbridge, and M. U. Sivananthan
Myocardial t1 mapping for detection of left ventricular myocardial fibrosis in chronic aortic regurgitation: pilot study.
Am. J. Roentgenol., December 1, 2006; 187(6): W630 - W635.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. G. Assomull, S. K. Prasad, J. Lyne, G. Smith, E. D. Burman, M. Khan, M. N. Sheppard, P. A. Poole-Wilson, and D. J. Pennell
Cardiovascular Magnetic Resonance, Fibrosis, and Prognosis in Dilated Cardiomyopathy
J. Am. Coll. Cardiol., November 21, 2006; 48(10): 1977 - 1985.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
C. B. Marcu, A. M. Beek, and A. C. van Rossum
Clinical applications of cardiovascular magnetic resonance imaging.
Can. Med. Assoc. J., October 10, 2006; 175(8): 911 - 917.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
K Debl, B Djavidani, S Buchner, C Lipke, W Nitz, S Feuerbach, G Riegger, and A Luchner
Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis
Heart, October 1, 2006; 92(10): 1447 - 1451.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346.
[Full Text] [PDF]

Home page
 EuropaceHome page
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 746 - 837.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
C. Ebeling Barbier, T. Bjerner, L. Johansson, L. Lind, and H. Ahlstrom
Myocardial Scars More Frequent Than Expected: Magnetic Resonance Imaging Detects Potential Risk Group
J. Am. Coll. Cardiol., August 15, 2006; 48(4): 765 - 771.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. A. Dumont, L. Monserrat, R. Soler, E. Rodriguez, X. Fernandez, J. Peteiro, A. Bouzas, B. Bouzas, and A. Castro-Beiras
Interpretation of electrocardiographic abnormalities in hypertrophic cardiomyopathy with cardiac magnetic resonance
Eur. Heart J., July 2, 2006; 27(14): 1725 - 1731.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Mandapaka, R. D'Agostino Jr, and W. G. Hundley
Does Late Gadolinium Enhancement Predict Cardiac Events in Patients With Ischemic Cardiomyopathy?
Circulation, June 13, 2006; 113(23): 2676 - 2678.
[Full Text] [PDF]

Home page
 BMJHome page
P. Spirito and C. Autore
Management of hypertrophic cardiomyopathy.
BMJ, May 27, 2006; 332(7552): 1251 - 1255.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Pieroni, C. Chimenti, F. De Cobelli, E. Morgante, A. Del Maschio, C. Gaudio, M. A. Russo, and A. Frustaci
Fabry's Disease Cardiomyopathy: Echocardiographic Detection of Endomyocardial Glycosphingolipid Compartmentalization
J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1663 - 1671.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
E Perugini, C Rapezzi, T Piva, O Leone, L Bacchi-Reggiani, L Riva, F Salvi, L Lovato, A Branzi, and R Fattori
Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance
Heart, March 1, 2006; 92(3): 343 - 349.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
T. Oosterhof, B. J. M. Mulder, H. W. Vliegen, and A. de Roos
Corrected Tetralogy of Fallot: Delayed Enhancement in Right Ventricular Outflow Tract
Radiology, December 1, 2005; 237(3): 868 - 871.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. Biagini, F. Coccolo, M. Ferlito, E. Perugini, G. Rocchi, L. Bacchi-Reggiani, C. Lofiego, G. Boriani, D. Prandstraller, F. M. Picchio, et al.
Dilated-Hypokinetic Evolution of Hypertrophic Cardiomyopathy: Prevalence, Incidence, Risk Factors, and Prognostic Implications in Pediatric and Adult Patients
J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1543 - 1550.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
B. Schumacher, F. H. Gietzen, H. Neuser, J. Schummelfeder, M. Schneider, S. Kerber, R. Schimpf, C. Wolpert, and M. Borggrefe
Electrophysiological Characteristics of Septal Hypertrophy in Patients With Hypertrophic Obstructive Cardiomyopathy and Moderate to Severe Symptoms
Circulation, October 4, 2005; 112(14): 2096 - 2101.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
P. Sipola, K. Lauerma, P. Jaaskelainen, M. Laakso, K. Peuhkurinen, H. Manninen, H. J. Aronen, and J. Kuusisto
Cine MR Imaging of Myocardial Contractile Impairment in Patients with Hypertrophic Cardiomyopathy Attributable to Asp175Asn Mutation in the {alpha}-Tropomyosin Gene
Radiology, September 1, 2005; 236(3): 815 - 824.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
H. Mahrholdt, A. Wagner, R. M. Judd, U. Sechtem, and R. J. Kim
Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies
Eur. Heart J., August 1, 2005; 26(15): 1461 - 1474.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
J C Moon, J Mogensen, P M Elliott, G C Smith, A G Elkington, S K Prasad, D J Pennell, and W J McKenna
Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I
Heart, August 1, 2005; 91(8): 1036 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
P. Knaapen, W. G. van Dockum, O. Bondarenko, W. E.M. Kok, M. J.W. Gotte, R. Boellaard, A. M. Beek, C. A. Visser, A. C. van Rossum, A. A. Lammertsma, et al.
Delayed Contrast Enhancement and Perfusable Tissue Index in Hypertrophic Cardiomyopathy: Comparison Between Cardiac MRI and PET
J. Nucl. Med., June 1, 2005; 46(6): 923 - 929.
[Abstract] [Full Text] [PDF]